{"id":7268,"date":"2024-11-05T08:00:00","date_gmt":"2024-11-05T07:00:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/kommentarer-gallande-mandagens-nyhet-om-licensavtal-for-en-long-acting-teknikplattform\/"},"modified":"2024-11-05T08:00:00","modified_gmt":"2024-11-05T07:00:00","slug":"kommentarer-gallande-mandagens-nyhet-om-licensavtal-for-en-long-acting-teknikplattform","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/kommentarer-gallande-mandagens-nyhet-om-licensavtal-for-en-long-acting-teknikplattform\/","title":{"rendered":"Kommentarer g\u00e4llande m\u00e5ndagens nyhet om licensavtal f\u00f6r en long-acting teknikplattform"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Ascendis Pharma, ett teknologiplattformsbolag med en prodrug teknologi annonserade ig\u00e5r att de har signerat ett licensavtal med Novo Nordisk. \u201dAscendis Pharma and Novo Nordisk har signerat ett avtal f\u00f6r samarbete, utveckling och kommersialisering av produkter inom metabola och kardiovaskul\u00e4ra sjukdomar med TransCon Teknologin. \u201dEn en-m\u00e5naders GLP-1 receptor agonist kommer att vara den ledande produktkandidaten.\u201d<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>Det \u00e4r och har varit f\u00f6rv\u00e4ntat att Novo Nordisk utv\u00e4rderar flera kandidater f\u00f6r att transformera typ-2 diabetes och obesitasbehandlingen till mindre frekventa doseringar. Det stod ocks\u00e5 klart under f\u00f6reg\u00e5ende veckas PODD (Partnerning opportunities in Drug Delivery) konferens att det \u00e4r en global trend mot mindre frekventa doseringar inom GLP-1 omr\u00e5det, s\u00e5 det \u00e4r realistiskt att det p\u00e5g\u00e5r parallella utvecklingar med olika teknologier och vi f\u00f6rv\u00e4ntar oss att flertalet teknologier har m\u00f6jlighet att n\u00e5 marknaden i detta enorma och v\u00e4xande omr\u00e5de. Under PODD och den p\u00e5g\u00e5ende BIO-Europe konferensen \u00e4r det ocks\u00e5 mycket klart att vi har flertalet bolag som \u00e4r intresserade av v\u00e5r PharmaShell plattform f\u00f6r att utveckla long acting GLP-1 och andra produkter.<\/p>\n<p>\u201dNanexas utv\u00e4rderingsprogram med Novo Nordisk forts\u00e4tter som planerat och vi bed\u00f6mer att vi kommer vara framg\u00e5ngsrika i att n\u00e5 de m\u00e5l som vi kommit \u00f6verens om inom tiden f\u00f6r deras exklusivitet\u201d s\u00e4ger Nanexas VD David Westberg.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-2376405b3437\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" rel=\"noopener\" target=\"_blank\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" rel=\"noopener\" target=\"_blank\">www.nanexa.com<\/a><\/p>\n<p>Bolagets Certified Adviser \u00e4r Carnegie Investment Bank AB (publ).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-c9ba281e2dde\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/8a85a5f6-8616-439e-9713-e30b2874542e\/kommentarer-gallande-mandagens-nyhet-om-licensavtal-for-en-long-acting-teknikplattform.pdf\" rel=\"noopener\" target=\"_blank\">Kommentarer g\u00e4llande m\u00e5ndagens nyhet om licensavtal f\u00f6r en long-acting teknikplattform<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ascendis Pharma, ett teknologiplattformsbolag med en prodrug teknologi annonserade ig\u00e5r att de har signerat ett licensavtal med Novo Nordisk. \u201dAscendis Pharma and Novo Nordisk har signerat ett avtal f\u00f6r samarbete, utveckling och kommersialisering av produkter inom metabola och kardiovaskul\u00e4ra sjukdomar med TransCon Teknologin. \u201dEn en-m\u00e5naders GLP-1 receptor agonist kommer att vara den ledande produktkandidaten.\u201d<\/p>\n","protected":false},"template":"","class_list":["post-7268","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kommentarer g\u00e4llande m\u00e5ndagens nyhet om licensavtal f\u00f6r en long-acting teknikplattform - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/kommentarer-gallande-mandagens-nyhet-om-licensavtal-for-en-long-acting-teknikplattform\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kommentarer g\u00e4llande m\u00e5ndagens nyhet om licensavtal f\u00f6r en long-acting teknikplattform - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Ascendis Pharma, ett teknologiplattformsbolag med en prodrug teknologi annonserade ig\u00e5r att de har signerat ett licensavtal med Novo Nordisk. \u201dAscendis Pharma and Novo Nordisk har signerat ett avtal f\u00f6r samarbete, utveckling och kommersialisering av produkter inom metabola och kardiovaskul\u00e4ra sjukdomar med TransCon Teknologin. \u201dEn en-m\u00e5naders GLP-1 receptor agonist kommer att vara den ledande produktkandidaten.\u201d\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/kommentarer-gallande-mandagens-nyhet-om-licensavtal-for-en-long-acting-teknikplattform\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/kommentarer-gallande-mandagens-nyhet-om-licensavtal-for-en-long-acting-teknikplattform\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/kommentarer-gallande-mandagens-nyhet-om-licensavtal-for-en-long-acting-teknikplattform\\\/\",\"name\":\"Kommentarer g\u00e4llande m\u00e5ndagens nyhet om licensavtal f\u00f6r en long-acting teknikplattform - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2024-11-05T07:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/kommentarer-gallande-mandagens-nyhet-om-licensavtal-for-en-long-acting-teknikplattform\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/kommentarer-gallande-mandagens-nyhet-om-licensavtal-for-en-long-acting-teknikplattform\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/kommentarer-gallande-mandagens-nyhet-om-licensavtal-for-en-long-acting-teknikplattform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Kommentarer g\u00e4llande m\u00e5ndagens nyhet om licensavtal f\u00f6r en long-acting teknikplattform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kommentarer g\u00e4llande m\u00e5ndagens nyhet om licensavtal f\u00f6r en long-acting teknikplattform - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/kommentarer-gallande-mandagens-nyhet-om-licensavtal-for-en-long-acting-teknikplattform\/","og_locale":"sv_SE","og_type":"article","og_title":"Kommentarer g\u00e4llande m\u00e5ndagens nyhet om licensavtal f\u00f6r en long-acting teknikplattform - Nanexa AB","og_description":"Ascendis Pharma, ett teknologiplattformsbolag med en prodrug teknologi annonserade ig\u00e5r att de har signerat ett licensavtal med Novo Nordisk. \u201dAscendis Pharma and Novo Nordisk har signerat ett avtal f\u00f6r samarbete, utveckling och kommersialisering av produkter inom metabola och kardiovaskul\u00e4ra sjukdomar med TransCon Teknologin. \u201dEn en-m\u00e5naders GLP-1 receptor agonist kommer att vara den ledande produktkandidaten.\u201d","og_url":"https:\/\/nanexa.com\/mfn_news\/kommentarer-gallande-mandagens-nyhet-om-licensavtal-for-en-long-acting-teknikplattform\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/kommentarer-gallande-mandagens-nyhet-om-licensavtal-for-en-long-acting-teknikplattform\/","url":"https:\/\/nanexa.com\/mfn_news\/kommentarer-gallande-mandagens-nyhet-om-licensavtal-for-en-long-acting-teknikplattform\/","name":"Kommentarer g\u00e4llande m\u00e5ndagens nyhet om licensavtal f\u00f6r en long-acting teknikplattform - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2024-11-05T07:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/kommentarer-gallande-mandagens-nyhet-om-licensavtal-for-en-long-acting-teknikplattform\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/kommentarer-gallande-mandagens-nyhet-om-licensavtal-for-en-long-acting-teknikplattform\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/kommentarer-gallande-mandagens-nyhet-om-licensavtal-for-en-long-acting-teknikplattform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Kommentarer g\u00e4llande m\u00e5ndagens nyhet om licensavtal f\u00f6r en long-acting teknikplattform"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7268","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7268"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}